Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 5, 1996, Pages 1099-1106

  Russell, Kenneth J ^a   Wiens, Linda W ^a   Demers, G William ^b   Galloway, Denise A ^b   Le, Tiep ^c   Rice, Glenn C ^c   Bianco, James A ^c   Singer, Jack W ^c   Groudine, Mark ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Cell Therapeutics Inc   (United States)

Author keywords

G1 checkpoint deficient cells; Methylxanthines

Indexed keywords

LISOFYLLINE; METHYLXANTHINE; PENTOXIFYLLINE; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CLONOGENESIS; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR SUPPRESSOR GENE;

CELL SURVIVAL; G1 PHASE; HUMANS; PENTOXIFYLLINE; PROTO-ONCOGENE PROTEINS P21(RAS); RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030458483     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00432-4     Document Type: Article

References (42)

1. 1. Bernhard, E. J.; McKenna, W. G.; Muschel, R. J. Cyclin expression and G2-phase delay after irradiation. Radiat. Res. Suppl. 138(1):S64-S67; 1994.
2. 2. Bookstein, R.; MacGrogan, D.; Hilsenbeck, S. G.; Sharkey, F.; Allred, D. C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53:3369-3373; 1993.
3. 3. Brachman, D. G.; Beckett, M.; Graves, D.; Haraf, D.; Yokes, E.; Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 53:3667-3669; 1993.
4. 4. Busse, P. M.; Bose, S. K.; Jones, R. W.; Tolmach, L. J. The action of caffeine on X-irradiated HeLa cells. III. Enhancement of X-ray-induced killing during G2 arrest. Radiat. Res. 76:292-307; 1978.
5. 5. Clarke, A. R.; Purdie, C. A.; Harrison, D. J.; Morris, R. G.; Bird, C. C.; Hooper, M. L.; Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852; 1993.
6. 6. Dalvi, R. R. Acute and chronic toxicity of caffeine: A review. Vet. Hum. Toxicol. 28:144-150; 1986.
7. 7. Demers, G. W.; Foster, S. A.; Halbert, C. L.; Galloway, D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by HPV 16 E7. Proc. Natl. Acad. Sci. USA 91:4382-4386; 1994.
8. 8. Fan, S.; Rivet, D. J.; Smith, M. L.; Zhan, Q.; Kohn, K. W.; Fornace, A. F., Jr; O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1649-1654; 1995.
9. 9. Halbert, C. L.; Demers, G. W.; Galloway, D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478; 1991.
10. 10. Harris, C. C.; Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1318-1327; 1993.
11. 11. Hasegawa, N.; Oka, Y.; Nakayama, F.; Bursten, S.; Raffin, T. A. The effect of inhibition of phosphatidic acid generation by lisofylline on sepsis-induced acute lung injury in mini-pigs. Am. J. Respir. Crit. Med. 151:A764; 1995.
12. 12. Iliakis, G.; Nusse, M. Effects of caffeine on X-irradiated synchronous, asynchronous and plateau phase mouse ascites cells: the importance of progression through the cell cycle for caffeine enhancement of killing. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 43:649-663; 1983.
13. 13. Jung, M.; Notario, V.; Dritschilo, A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res. 50:97-102; 1992.
14. 14. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311; 1991.
15. 15. Kessis, T. D.; Slebos, R. J.; Nelson, W. G.; Kastan, M. B.; Plunkett, B. S.; Han, S. M.; Lorincz, A. T.; Hedrick, L.; Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA 90:3988-3992; 1993.
16. 16. Kuerbitz, S. J.; Plunkett, B. S.; Walsh, W. V.; Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495; 1992.
17. 17. Lee, J. M.; Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90:5742-5746; 1993.
18. 18. Lehman, T. A.; Bennett, W. P.; Metcalf, R. A.; Welsh, J. A.; Ecker, J.; Modali, R. V.; Ullrich, S.; Romano, J. W.; Appella, E.; Testa, J. R.; Gerwin, B. I.; Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51:4090-4096; 1991.
19. 19. Livingstone, L. R.; White, A.; Sprouse, J.; Livanos, E.; Jacks, T.; Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935; 1992.
20. 20. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967; 1993.
21. 21. Lowe, S. W.; Schmitt, E. M.; Smith, S. W.; Osborne, B. A.; Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849; 1993.
22. 22. McIlwrath, A. J.; Vasey, P. A.; Ross, G. M.; Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res. 54:3718-3722; 1994.
23. 23. Musk, S. R. Reduction of radiation-induced cell cycle blocks by caffeine does not necessarily lead to increased cell killing. Radiat. Res. 125:262-266; 1991.
24. 24. Musk, S. R.; Steel, G. G. Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity. Int. J. Radiat. Biol. 57:1105-1112; 1990.
25. 25. Nusse, M.; Egner, H. J. Can nocodazole, an inhibitor of microtubule formation, be used to synchronize mammalian cells? Accumulation of cells in mitosis studied by two parameter flow cytometry using acridine orange and by DNA distribution analysis. Cell Tissue Kinet. 17:13-23; 1984.
26. 26. O 'Connor, P. M.; Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin. Cancer Biol. 3:409-416; 1992.
27. 27. O'Connor, P. M.; Jackman, J.; Jondle, D.; Bhatia, K.; Magrath, I.; Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 53:4776-4780; 1993.
28. 28. Powell, S. N.; DeFrank, J. S.; Connell, P.; Eogan, M.; Preffer, F.; Dombkowski, D.; Tang, W.; Friend, S. Differential sensitivity of p53- and p53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 55:1643-1648; 1995.
29. 29. Rabinovitch, P. S. Practical considerations for DNA content and cell cycle analysis. In: Bauer, K. D.; Dugue, R. R.; Shankey, T. V., eds. Clinical flow cytometry: Principles and applications. Baltimore: William and Wilkens; 1993:117-142.
30. 30. Rice, G. C.; Brown, P. A.; Nelson, R. J.; Bianco, J. A.; Singer, J. W.; Bursten, S. Protection from endotoxic shock in mice by pharmacological inhibition of phosphatidic acid. Proc. Natl. Acad. Sci. USA 91:3857-3861; 1994.
31. 31. Rice, G. C.; Rosen, J.; Weeks, R.; Michnick, J.; Bursten, S.; Bianco, J. A.; Singer, J. W. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1:254-266; 1994.
32. 32. Roberts, J. J. Mechanism of potentiation by caffeine of genotoxic damage induced by physical and chemical agents. In: Collins, A.; Downes, C. S.; Johson, R. T., eds. DNA repair and its inhibition. Oxford: IRL Press; 1984:193-215.
33. 33. Russell, K. J.; Wiens, L. W.; Galloway, D. A.; Plon, S. E.; Groudine, M. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and competent cells. Cancer Res. 55:1639-1642; 1995.
34. 34. Shapiro, C. L.; Dezube, B. J.; Wright, J.; Teicher, B. A.; Pardee, A. B.; Rei, E., III; Henderson, I. C. Phase I-II trial of thiotepa and pentoxifylline in advanced breast cancer. In: Mandell, G. L.; Novick, W. J., Jr, eds. Pentoxifylline, leukocytes, and cytokines. Summerville, NJ: Hoechst-Roussel Pharmaceutical; 1992:34-39.
35. 35. Silvestrini, R.; Benini, E.; Daidone, M. G.; Veneroni, S.; Boracchi, P.; Cappelletti, V.; Di, F. G.; Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 85:965-970; 1993.
36. 36. Singer, J. W. (unpublished data); 1995.
37. 37. Slichenmyer, W. J.; Nelson, W. G.; Slebos, R. J.; Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:4164-4168; 1993.
38. 38. Su, L.-N.; Little, J. B. Prolonged cell cycle delay in radioresistant human cell lines transfected with activated ras oncogene and/or simian virus 40T-antigen. Radiat Res. 133:73-79; 1993.
39. 39. Teicher, B. A.; Holden, S. A.; Herman, T. S.; Epelbaum, R.; Pardee, A. B.; Debuze, B. J. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res. 11:1555-560; 1991.
40. 40. Thompson, J. A.; Neumanaitis, J.; Jain, V.; Bakke, L.; Fefer, A.; Singer, J. W.; Bianco, J. A. Preliminary results of a phase I trial of CT-1501R in cancer patients receiving high-dose interleukin-2. Blood 81:363a; 1993.
41. 41. Weinert, T. A.; Hartwell, L. H. The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317-322; 1988.
42. 42. Werness, B. A.; Levine, A. J.; Howley, P. M. Association of human papillomavirus types 16 and 18 E6 protein with p53. Science 248:76-79; 1990.